EMORFAZONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H17N3O3
Molecular Weight	239.271
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC1=C(C=NN(C)C1=O)N2CCOCC2

InChI

InChIKey=URJQOOISAKEBKW-UHFFFAOYSA-N

InChI=1S/C11H17N3O3/c1-3-17-10-9(8-12-13(2)11(10)15)14-4-6-16-7-5-14/h8H,3-7H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C11H17N3O3
Molecular Weight	239.271
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1545477
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/7201806, http://www.ncbi.nlm.nih.gov/pubmed/6172134

Emorfazone is an analgetic agent that was developed by Morishita Pharmaceutical in Japan. The drug was tested for its ability to treat dental pain and inflammation in double blind study and was shown to be effective, however the exact mechanism of its action still remains unknown. Moreover, it is supposed that the effect is not mediated by interaction with opioids receptors or with prostaglandins synthesis.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dental pain and inflammation 1 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1545477	Primary		Phase II 1147	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1545477/	unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1545477/	Sources: https://pubmed.ncbi.nlm.nih.gov/1545477/

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
3-Chloro-6-[4-(2-pyrid-yl)piperazin-1-yl]pyridazine.	2009-12-04	21580140

Patents

Sample Use Guides

In Vivo Use Guide

Emorfazone 400 mg thrice daily for two days followed by emorfazone 200 mg thrice daily for the next four days.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:32:43 GMT 2025` Edited by `admin` on `Mon Mar 31 18:32:43 GMT 2025`
Record UNII	V93U9DH62C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EMORFAZONE

Official Name

English

PENTOIL

Preferred Name

English

Emorfazone [WHO-DD]

Common Name

English

EMORFAZONE [JAN]

Common Name

English

emorfazone [INN]

Common Name

English

4-ETHOXY-2-METHYL-5-MORPHOLINO-3(2H)-PYRIDAZINONE

Systematic Name

English

EMORFAZONE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257